Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic

H. Moualla; D. A. Mills; R. Hromas; C. F. Verschraegen

doi:10.1358/dof.2009.034.05.1370796

Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic

H. Moualla, D. A. Mills, R. Hromas, C. F. Verschraegen

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

(Chemical Equation Presented) Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharma for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II, causing replication-dependent DNA damage in the S-phase of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemia (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.

Original language	English (US)
Pages (from-to)	363-374
Number of pages	12
Journal	Drugs of the Future
Volume	34
Issue number	5
DOIs	https://doi.org/10.1358/dof.2009.034.05.1370796
State	Published - May 2009
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2009.034.05.1370796

Cite this

@article{f140f763a1ca46f38d02542b40901c7d,

title = "Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic",

abstract = "(Chemical Equation Presented) Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharma for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II, causing replication-dependent DNA damage in the S-phase of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemia (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.",

author = "H. Moualla and Mills, {D. A.} and R. Hromas and Verschraegen, {C. F.}",

year = "2009",

month = may,

doi = "10.1358/dof.2009.034.05.1370796",

language = "English (US)",

volume = "34",

pages = "363--374",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "5",

}

TY - JOUR

T1 - Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic

AU - Moualla, H.

AU - Mills, D. A.

AU - Hromas, R.

AU - Verschraegen, C. F.

PY - 2009/5

Y1 - 2009/5

N2 - (Chemical Equation Presented) Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharma for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II, causing replication-dependent DNA damage in the S-phase of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemia (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.

AB - (Chemical Equation Presented) Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharma for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II, causing replication-dependent DNA damage in the S-phase of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemia (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.

UR - http://www.scopus.com/inward/record.url?scp=76649135182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76649135182&partnerID=8YFLogxK

U2 - 10.1358/dof.2009.034.05.1370796

DO - 10.1358/dof.2009.034.05.1370796

M3 - Review article

AN - SCOPUS:76649135182

SN - 0377-8282

VL - 34

SP - 363

EP - 374

JO - Drugs of the Future

JF - Drugs of the Future

IS - 5

ER -

Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this